{
    "title": "Actelion lifts 2014 profit view on strong Opsumit launch",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2801287/Actelion-lifts-2014-profit-view-strong-Opsumit-launch.html",
    "date": "2014-10-21",
    "keywords": [
        "opsumit",
        "actelion",
        "drug",
        "pah",
        "percent",
        "profit",
        "year",
        "company",
        "clozel",
        "launch",
        "october",
        "caroline",
        "tuesday",
        "start",
        "treatment",
        "approval",
        "tracleer",
        "patent",
        "protection",
        "quarter",
        "growth",
        "stock",
        "combination",
        "view",
        "gmt",
        "email",
        "copleyzurich",
        "guidance",
        "time",
        "heart",
        "biotech",
        "uptake",
        "hypertension",
        "europe",
        "end",
        "firm",
        "flagship",
        "product",
        "operating",
        "medicaid",
        "rise",
        "millionactelion",
        "core",
        "exchange",
        "percentage",
        "trade",
        "gmtsarasin",
        "analyst",
        "chi",
        "tranbraendli",
        "rating",
        "noterival",
        "treatmentsother",
        "competition",
        "september",
        "adcirca",
        "alternative",
        "jeanpaul",
        "use",
        "way",
        "selexipag",
        "june",
        "statement",
        "health",
        "latestage",
        "trial",
        "clostridium",
        "difficile",
        "diarrhoeaclozel",
        "aim",
        "marketthe",
        "performer",
        "bluechip",
        "index",
        "peer",
        "medium",
        "dollar",
        "franc",
        "reporting",
        "copley",
        "editing",
        "dwarakanath",
        "jane",
        "baird"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}